On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
